Drug Technologies and Development - Penwest Pharmaceutical Co.


		Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. Penwest is currently developing A0001, a coenzyme Q analog drug candidate for inherited mitochondrial respiratory chain diseases. Penwest is also applying its drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations with partners.
		RECENT PRESS RELEASES June 24, 2009 Penwest Announces That the Results of Its Annual Meeting Have Been Certified June 17, 2009 Penwest Enters Into Third Research and Development Agreement With Otsuka Pharmaceutical June 10, 2009 Penwest Announces Preliminary Vote Count At Annual Meeting	Click here to learn about licensing our technologies
		PRODUCT PIPELINE

2008 Penwest Pharmaceuticals Co.
Terms and Conditions, Privacy Statement, & Safe Harbor